[go: up one dir, main page]

TN2009000036A1 - Therapeutic methods for treating vascular eye disorders with dll4 antagonists - Google Patents

Therapeutic methods for treating vascular eye disorders with dll4 antagonists

Info

Publication number
TN2009000036A1
TN2009000036A1 TN2009000036A TN2009000036A TN2009000036A1 TN 2009000036 A1 TN2009000036 A1 TN 2009000036A1 TN 2009000036 A TN2009000036 A TN 2009000036A TN 2009000036 A TN2009000036 A TN 2009000036A TN 2009000036 A1 TN2009000036 A1 TN 2009000036A1
Authority
TN
Tunisia
Prior art keywords
ischemic
dii4
retinopathy
therapeutic methods
inhibiting
Prior art date
Application number
TN2009000036A
Other languages
English (en)
Inventor
Stanley J Wiegand
Nicholas J Papadopoulos
Ivan B Lobov
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of TN2009000036A1 publication Critical patent/TN2009000036A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TN2009000036A 2006-08-07 2009-02-03 Therapeutic methods for treating vascular eye disorders with dll4 antagonists TN2009000036A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83600306P 2006-08-07 2006-08-07
PCT/US2007/017546 WO2008019144A2 (fr) 2006-08-07 2007-08-07 Procédés thérapeuthiques pour traiter des troubles vasculaires de l'oeil par des antagonistes de dll4

Publications (1)

Publication Number Publication Date
TN2009000036A1 true TN2009000036A1 (en) 2010-08-19

Family

ID=38904599

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000036A TN2009000036A1 (en) 2006-08-07 2009-02-03 Therapeutic methods for treating vascular eye disorders with dll4 antagonists

Country Status (32)

Country Link
US (1) US20080181893A1 (fr)
EP (1) EP2054082B1 (fr)
JP (1) JP5529536B2 (fr)
KR (1) KR101497355B1 (fr)
CN (1) CN101500605B (fr)
AU (1) AU2007281916B2 (fr)
BR (1) BRPI0716424B8 (fr)
CA (1) CA2660235C (fr)
CO (1) CO6150190A2 (fr)
CR (1) CR10627A (fr)
DK (1) DK2054082T3 (fr)
ES (1) ES2398253T3 (fr)
GT (1) GT200900029A (fr)
HR (1) HRP20130271T1 (fr)
IL (1) IL196612A (fr)
MA (1) MA30667B1 (fr)
ME (1) ME00591A (fr)
MX (1) MX2009000674A (fr)
MY (1) MY150092A (fr)
NO (1) NO341857B1 (fr)
NZ (1) NZ574794A (fr)
PL (1) PL2054082T3 (fr)
PT (1) PT2054082E (fr)
RS (1) RS52685B (fr)
RU (1) RU2429876C2 (fr)
SG (1) SG174033A1 (fr)
SI (1) SI2054082T1 (fr)
SV (1) SV2009003161A (fr)
TN (1) TN2009000036A1 (fr)
UA (1) UA95304C2 (fr)
WO (1) WO2008019144A2 (fr)
ZA (1) ZA200900337B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101477824B1 (ko) 2006-09-29 2015-01-02 온코메드 파마슈티칼스, 인크. 암의 진단 및 치료를 위한 조성물 및 방법
WO2008091222A1 (fr) * 2007-01-26 2008-07-31 Bioinvent International Ab Inhibiteurs de la signalisation dll4 et utilisations associees
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
BRPI0913476A2 (pt) * 2008-09-10 2015-12-01 Genentech Inc "usos de um antagonista tspan12 e usos de um antagonista de norrin"
AU2009294415B2 (en) * 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
WO2010054007A1 (fr) 2008-11-07 2010-05-14 Fabrus Llc Bibliothèques combinatoires d'anticorps et leurs utilisations
WO2011008641A1 (fr) 2009-07-13 2011-01-20 Beth Israel Deaconess Medical Center, Inc. Méthodes de modulation de l’angiogenèse et traitement de maladies associées à l’angiogenèse
SG178930A1 (en) 2009-08-29 2012-04-27 Abbott Lab Therapeutic dll4 binding proteins
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US8883145B2 (en) * 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
MX348312B (es) * 2010-03-02 2017-06-06 Abbvie Inc Proteínas terapéuticas de enlace dll4.
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JP6170496B2 (ja) 2011-09-23 2017-07-26 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
WO2014062659A2 (fr) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Méthodes de traitement de maladies oculaires
EP2914961A4 (fr) 2012-10-31 2016-04-20 Oncomed Pharm Inc Méthodes et surveillance d'un traitement par un antagoniste de dll4
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
EP3212233B1 (fr) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Thérapie combinée pour le traitement d'une maladie
JP6967003B2 (ja) 2015-09-23 2021-11-17 メレオ バイオファーマ ５ インコーポレイテッド がんの処置のための方法および組成物
US11679126B2 (en) 2016-11-17 2023-06-20 Chldren's Medical Center Corporation Methods to enhance microvascular engraftment of bioengineered and primary tissues
WO2023063842A1 (fr) 2021-10-12 2023-04-20 Общество с ограниченной ответственностью "Пальмира Биофарма" Séquence nucléotidique codant une protéine de fusion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US20070213266A1 (en) * 2005-09-01 2007-09-13 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of Delta-like 4
MX2008015532A (es) * 2006-06-06 2008-12-18 Genentech Inc Composiciones y metodos para la modulacion del desarrollo vascular.

Also Published As

Publication number Publication date
IL196612A (en) 2012-02-29
SV2009003161A (es) 2010-02-01
EP2054082B1 (fr) 2012-12-26
ME00591B (fr) 2011-12-20
WO2008019144A3 (fr) 2008-03-27
ES2398253T3 (es) 2013-03-14
MY150092A (en) 2013-11-29
GT200900029A (es) 2009-11-17
UA95304C2 (ru) 2011-07-25
WO2008019144A2 (fr) 2008-02-14
KR101497355B1 (ko) 2015-03-02
CR10627A (es) 2009-04-14
HRP20130271T1 (hr) 2013-04-30
DK2054082T3 (da) 2013-01-21
MX2009000674A (es) 2009-02-04
IL196612A0 (en) 2011-08-01
BRPI0716424B8 (pt) 2021-05-25
RU2429876C2 (ru) 2011-09-27
JP2010500355A (ja) 2010-01-07
AU2007281916B2 (en) 2012-06-28
MA30667B1 (fr) 2009-08-03
AU2007281916A1 (en) 2008-02-14
PT2054082E (pt) 2013-03-07
US20080181893A1 (en) 2008-07-31
CN101500605A (zh) 2009-08-05
PL2054082T3 (pl) 2013-05-31
NO341857B1 (no) 2018-02-12
CA2660235A1 (fr) 2008-02-14
CN101500605B (zh) 2014-04-30
CO6150190A2 (es) 2010-04-20
HK1137339A1 (en) 2010-07-30
ME00591A (en) 2011-12-20
BRPI0716424A2 (pt) 2014-05-20
NZ574794A (en) 2011-06-30
ZA200900337B (en) 2009-12-30
RS52685B (sr) 2013-08-30
SI2054082T1 (sl) 2013-04-30
RU2009107921A (ru) 2010-09-20
KR20090039823A (ko) 2009-04-22
NO20090984L (no) 2009-03-04
CA2660235C (fr) 2015-09-22
EP2054082A2 (fr) 2009-05-06
SG174033A1 (en) 2011-09-29
JP5529536B2 (ja) 2014-06-25
BRPI0716424B1 (pt) 2018-06-26

Similar Documents

Publication Publication Date Title
TN2009000036A1 (en) Therapeutic methods for treating vascular eye disorders with dll4 antagonists
Park et al. Iatrogenic retinal artery occlusion caused by cosmetic facial filler injections
Faghihi et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema
Bae et al. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial
US20140066786A1 (en) Method and Apparatus For Improved Wound Healing and Enhancement of Rehabilitation
US20100105993A1 (en) Methods and apparatus for noninvasive ischemic conditioning
WO2008148045A1 (fr) Procédés et appareil pour un conditionnement ischémique non effractif
Wang et al. Preclinical efficacy of human Albumin in subarachnoid hemorrhage
Manfredini et al. Acute oxygenation changes on ischemic foot of a novel intermittent pneumatic compression device and of an existing sequential device in severe peripheral arterial disease
Sheth Does pregnancy accelerate the rate of progression of diabetic retinopathy?: an update
Castejon et al. Effect of acute increase in blood pressure on intraocular pressure in pigs and humans
An et al. Neovascular glaucoma due to branch retinal vein occlusion combined with branch retinal artery occlusion
Yamaji et al. Evaluation of arteriovenous crossing sheathotomy for branch retinal vein occlusion by fluorescein videoangiography and image analysis
Zhu et al. Effect of enhanced extracorporeal counterpulsation in patients with non-arteritic anterior ischaemic optic neuropathy
Chang et al. Corneal penetration by tarantula hairs
RU2575966C2 (ru) Способ лечения неоваскулярной глаукомы
Uva et al. The effect of timolol-dorzolamide and timolol-pilocarpine combinations on ocular blood flow in patients with glaucoma
CN117752663B (zh) 一种调节神经病变的方法
PEARCE et al. Amantadine hydrochloride: alteration in peripheral circulation
Kalina et al. Proliferative retinopathy after treatment of carotid-cavernous fistulas
US20130251823A1 (en) Angiogenesis regulating composition and method for regulating angiogenesis
CY1113840T1 (el) Χρηση ανταγωνιστων d114 σε ισχαιμικη βλαβη ή αγγειακη ανεπαρκεια
Sohn et al. Arteriovenous sheathotomy for persistent macular edema in branch retinal vein occlusion
Kayikcioglu et al. Miliary microemboli of the retinal arterioles and choriocapillaris after subcutaneous injection of triamcinolone acetonide
Kohler et al. Periodic whole body acceleration: a novel therapy for cardiovascular disease